Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
, 14 (3), 282-3

Cyclic Combination Chemotherapy in Advanced Adenocarcinoma of the Lung: Comparison of Two FAM Schedules

Comparative Study

Cyclic Combination Chemotherapy in Advanced Adenocarcinoma of the Lung: Comparison of Two FAM Schedules

W K Lam et al. Cancer Chemother Pharmacol.

Abstract

Forty patients with advanced adenocarcinoma of the lung were treated by two FAM chemotherapy schedules. Group A (20 patients) received Futraful, adriamycin, and mitomycin C, and group B (20 patients) received 5-fluorouracil, adriamycin, and mitomycin C. The response/stabilization rate was greater for group B (4 partial responses + 4 cases of stable disease) than for group A (no responders + 5 cases of stable disease), and the median survival was longer for group B (32 weeks) than for group A (22 weeks), although the differences did not reach statistical significance in either case (P greater than 0.05). Myelotoxicity was mild in both schedules. Further studies of the two FAM schemes at an escalated dose would be worthwhile.

Similar articles

See all similar articles

Cited by 1 article

References

    1. Cancer. 1979 Apr;43(4):1183-8 - PubMed
    1. Semin Oncol. 1983 Mar;10(1):111-22 - PubMed
    1. Med Pediatr Oncol. 1978;4(1):35-42 - PubMed
    1. Cancer Chemother Pharmacol. 1980;4(4):271-3 - PubMed
    1. Clin Oncol. 1981 Jun;7(2):131-9 - PubMed

Publication types

LinkOut - more resources

Feedback